{
  "trial_id": "NCT00234494",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Previously untreated or relapsed locally advanced or metastatic transitional cell carcinoma of the bladder.",
      "label": "unknown"
    },
    {
      "criterion": "Relapsed patients may have received prior chemotherapy \u2265 one year prior to study registration as part of a neoadjuvant or adjuvant regimen and must not have had intervening therapy from the end of that treatment until study entry.",
      "label": "unknown"
    },
    {
      "criterion": "Measurable disease as per RECIST.",
      "label": "met"
    },
    {
      "criterion": "Prior radiation therapy, immunotherapy, cytokine, biologic or vaccine therapy must be greater than 28 days prior to being registered for protocol therapy.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "No known central nervous system metastasis. (imaging of brain only required if clinically indicated)",
      "label": "met"
    },
    {
      "criterion": "No prior organ allograft.",
      "label": "unknown"
    },
    {
      "criterion": "No history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.",
      "label": "unknown"
    },
    {
      "criterion": "No evidence of bleeding diathesis or coagulopathy.",
      "label": "met"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "39",
    "trial_id": "NCT00234494",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}